{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:13:38Z","timestamp":1783577618921,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Zacharon Pharmaceuticals"},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["SBIR R43 NS077513"],"award-info":[{"award-number":["SBIR R43 NS077513"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lysosomal Disease Network"},{"name":"The Lysosomal Disease Network","award":["U54-NS065768"],"award-info":[{"award-number":["U54-NS065768"]}]},{"name":"National Institute of Health (NIH) Rare Diseases Clinical Research Network"},{"name":"NIH Office of Rare Diseases Research"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ymgme.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T19:06:30Z","timestamp":1568228790000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I"],"prefix":"10.1016","volume":"129","author":[{"given":"Moin U.","family":"Vera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Q.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Victoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merry B.","family":"Passage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett E.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda E.","family":"Polgreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia I.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.09.001_bb0005","series-title":"Metab. Mol. Bases Inherit. Dis","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2019.09.001_bb0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharisosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human \u03b1-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0025","first-page":"95","article-title":"Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (Hurler syndrome) treated with hematopoietic cell transplantation","volume":"29","author":"Kunin-Batson","year":"2016","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","article-title":"The clinical outcome of Hurler syndrome after stem cell transplantation","volume":"14","author":"Aldenhoven","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgme.2015.07.005","article-title":"Mucopolysaccharidosis I intrathecal research collaborative, safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I","volume":"116","author":"Dickson","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jpeds.2016.08.033","article-title":"Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I","volume":"178","author":"Laraway","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0050","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/clinchem\/35.7.1472","article-title":"Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses","volume":"35","author":"de Jong","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/000456329403100309","article-title":"Mucopolysaccharidoses screening: dimethylmethylene blue versus Alcian blue","volume":"31","author":"de Jong","year":"1994","journal-title":"Ann. Clin. Biochem. An Int. J. Biochem. Lab. Med."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.aca.2016.06.054","article-title":"UPLC-MS\/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses","volume":"936","author":"Auray-Blais","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.ymgme.2019.09.001_bb0065","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1021\/ac2001077","article-title":"A comprehensive compositional analysis of heparin\/heparan sulfate-derived disaccharides from human serum","volume":"83","author":"Wei","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omtm.2017.05.009","article-title":"Clearance of heparan sulfate and attenuation of CNS pathology by intracerebroventricular BMN 250 in Sanfilippo type B mice","volume":"6","author":"Aoyagi-Scharber","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ymgme.2012.02.003","article-title":"Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"106","author":"Dickson","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0085","doi-asserted-by":"crossref","first-page":"33674","DOI":"10.1074\/jbc.M804288200","article-title":"Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling","volume":"283","author":"Lawrence","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/bmme.1996.0044","article-title":"Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I","volume":"58","author":"Kakkis","year":"1996","journal-title":"Biochem. Mol. Med."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/mgme.2000.3140","article-title":"Enzyme replacement therapy in feline mucopolysaccharidosis I","volume":"72","author":"Kakkis","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme \u03b1-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0110","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1203\/00006450-199606000-00019","article-title":"Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival","volume":"39","author":"Vogler","year":"1996","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0115","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1073\/pnas.0405042101","article-title":"Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier","volume":"101","author":"Urayama","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0120","series-title":"Treatment of CNS lysosomal storage with high-dose intravenous enzyme replacement therapy in tolerant MPS I dogs, abstract","first-page":"2351A","author":"Dickson","year":"2006"},{"key":"10.1016\/j.ymgme.2019.09.001_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","article-title":"Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: a phase IIb randomized trial","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajmg.1320460222","article-title":"Long-term outcome of Hurler syndrome following bone marrow transplantation","volume":"46","author":"Whitley","year":"1993","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0135","first-page":"64","article-title":"Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome","volume":"13","author":"Eisengart","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0140","first-page":"286","article-title":"Glycan-based biomarkers for mucopolysaccharidoses","volume":"112","author":"Lawrence","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0145","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.clinbiochem.2014.06.012","article-title":"Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population","volume":"47","author":"Komosinska-Vassev","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0150","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-2944(75)90064-2","article-title":"Lack of relationship between blood and urine levels of glycosaminoglycans and lysomal enzymes","volume":"12","author":"Erickson","year":"1975","journal-title":"Biochem. Med."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2017.12.007","article-title":"Glycosaminoglycan fragments as a measure of disease burden in the mucopolysaccharidosis type I mouse","volume":"123","author":"Saville","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2019.09.001_bb0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jpba.2013.06.026","article-title":"Plasmatic dermatan sulfate and chondroitin sulfate determination in mucopolysaccharidoses","volume":"85","author":"Volpi","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2009.10.001","article-title":"Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry","volume":"99","author":"Tomatsu","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ab.2010.04.002","article-title":"Determination of urinary oligosaccharides by high-performance liquid chromatography\/electrospray ionization\u2013tandem mass spectrometry: application to Hunter syndrome","volume":"402","author":"Nielsen","year":"2010","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0185","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1073\/pnas.1818333116","article-title":"Substrate binding mode and catalytic mechanism of human heparan sulfate d-glucuronyl C5 epimerase","volume":"116","author":"Debarnot","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0190","doi-asserted-by":"crossref","first-page":"20996","DOI":"10.1074\/jbc.M112.359885","article-title":"Uncovering biphasic catalytic mode of C5-epimerase in heparan sulfate biosynthesis","volume":"287","author":"Sheng","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0195","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in the canine model of mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0200","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.omtm.2017.09.008","article-title":"A humoral immune response alters the distribution of enzyme replacement therapy in murine mucopolysaccharidosis type I","volume":"8","author":"Le","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2019.09.001_bb0205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219304329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219304329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:26:22Z","timestamp":1761089182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719219304329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1096719219304329"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.09.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}